周期素依赖激酶2在非小细胞肺癌中的表达及其临床意义

目的 观察细胞周期因子周期素依赖激酶2(CDK2)在非小细胞肺癌(NSCLC)中的表达，探讨其临床意义。方法 采用免疫组织化学链霉素亲生物蛋白—过氧化酶(S—P)法，观察66例临床资料完整的NSCLC组织和12例正常肺组织中CDK2的表达，并对其与临床预后的关系进行相关分析。结果 在66例NSCLC患者中，CDK2在细胞核呈阳性免疫反应，其阳性表达率为84．85％。CDK2表达对年龄、性别、组织学类型、pTNM分期和淋巴结转移均无显著的影响(P＞O．05)，而对肿瘤的大小、病理分级有显著影响(P＜O．05)。CDK2表达阳性者与阴性者比较生存时间明显缩短(P＝O．O14)，CDK2阳性患者估计增加相对风险为2．5。结论 CDK2在NSCLC组织中细胞核呈阳性免疫反应，其过度表达与NSCLC患者临床病理特征和预后不良有关。

Expression of cyclin-dependent kinase 2 in non-small cell lung cancer and its clinical significance

Objective To investigate the clinical significance of expression of cyclin-dependent kinase 2(CDK2) in non-small cell lung cancer (NSCLC). Methods Specimens of formalin-fixed, paraffin embedded NSCLC ( n =66) and normal lung tissues ( n =12) were analyzed by streptavidin/peroxidase conjugate method of immunohistochemistry (S-P) for the expression of CDK2 and its relationship with clinical prognosis. Results In 66 NSCLC cases, the expression of CDK2 showed nuclear immunoreactivity. The positive expression rates of CDK2 was 84.85%. Some of the clinical parameters (age, sex, histology, stage, lymph node involvement) had no significant correlation with expression of CDK2,but pathologic grade and extent of tumour size had a significant correlation with expression of CDK2( P <0.05). The time of survival was significantly shorter in patients with CDK2 positive than those with CDK2 negative ( P =0.014). The estimated increased relative risk for patients with CDK2 positive tumours was 2.5 . Conclusion The expression of CDK2 shows nuclear immunoreactivity in NSCLC tissues, its over-expression is related to some of the clinical pathological parameters and the poor prognosis of NSCLC patients.